Excellent presentation, I agree @wisdomofsilence. Things are...

Excellent presentation, I agree @wisdomofsilence. Things are evolving nicely for PIQ. There is massive potential here for a Pharma deal. Not just for PromarkerD & existing collaboration with Janssen & use of this test in their groundbreaking Type2 diabetes drug in further indications for CKD & cardiovascular disease, but also analytics in drug development.

Also, additional testing in the pipeline, which I’m really excited to see a blood test for Endometriosis, a condition that affects 1:10 women, and early diagnosis has the potential to be life changing with this condition & a simple blood test before putting women through the risk of a general anaesthetic & exploratory surgery for a definitive diagnosis is a far better health care option. If surgery is needed post diagnosis, then so be it. They are progressing well with this test from most recent ANN mentioning this.

Also noted PIQ in discussions globally as per the presentation. Deals already in place. The presentation is succinct & easy to read, not bogged down in technical stuff & the potential upside for the company is glaringly obvious. The utilisation of PromarkerD in a major Pharmaceutical trial that was highly successful, also gives further weight to PIQ’s IP. IMO. I think the words they used for that is “de-risked”. Best wishes all.